Fake Reviews, Hidden Terms: The Telehealth Company Selling GLP-1 Weight-Loss Memberships

The operators of telemedicine company Southern Health Solutions, Inc., doing business as Next Medical and NextMed, have agreed to settle charges that they used deceptive claims about costs and weight loss, fake reviews, and fake testimonials to lure consumers into buying weight-loss membership programs built around GLP-1 medications.DOCUMENTED

The proposed order requires NextMed and its principals to pay $150,000, expected to be used to provide refunds to consumers affected by the company's marketing practices.DOCUMENTED

Riding a surge in demand

GLP-1 medications have become one of the most sought-after categories of prescription treatment in recent years, driven by their effectiveness for weight loss and the intense consumer and media attention that effectiveness has generated.REVIEWED That surge in demand created an opening for telehealth companies to market rapid access to these medications, often at prices and terms that, according to the complaint against NextMed, did not match what the company actually delivered.DOCUMENTED

What the complaint alleges

According to the complaint, NextMed made deceptive claims about the actual cost of its weight-loss membership programs, about the results consumers could expect from participating, and bolstered its marketing with fake reviews and fake testimonials designed to make the program appear more effective and trustworthy than the underlying evidence supported.DOCUMENTED The complaint also alleges the company's membership programs contained hidden terms and conditions — contractual details material to a consumer's decision to sign up that were not clearly and conspicuously disclosed before the consumer committed to the program.DOCUMENTED

Why pricing transparency matters especially for prescription weight-loss programs

GLP-1 medications are typically expensive, and pricing structures for telehealth-delivered weight-loss programs often combine a membership or subscription fee with the separate cost of the medication itself, creating multiple potential points where a consumer's actual total cost could diverge sharply from what marketing materials imply.REVIEWED A consumer comparing NextMed's advertised price against a traditional in-person prescription pathway would need transparent, complete cost information to make that comparison meaningfully — information the complaint alleges NextMed did not provide.REVIEWED

The complaint alleges NextMed's marketing combined deceptive cost claims with fake reviews and hidden membership terms — a combination that made the program appear both cheaper and more effective than what consumers experienced.

What the settlement requires

Beyond the $150,000 monetary payment, a settlement of this kind typically also includes injunctive provisions barring the specific deceptive practices identified in the complaint — prohibiting future misrepresentations about program costs, weight-loss outcomes, and the authenticity of reviews or testimonials used in marketing.REVIEWED Requiring clear and conspicuous disclosure of membership terms before a consumer signs up addresses the hidden-terms allegation directly, aiming to ensure future customers see the complete cost and commitment structure before, not after, agreeing to join.REVIEWED

Part of a broader wave of telehealth weight-loss scrutiny

The NextMed case arrived amid growing regulatory and public attention to the telehealth weight-loss industry generally, as a rapidly expanding market for GLP-1 access has drawn numerous new entrants competing aggressively for the same pool of consumers seeking these treatments.REVIEWED That competitive pressure has, in cases like this one, produced marketing claims that outpaced what companies could actually substantiate — a pattern regulators have flagged as a recurring risk whenever a single drug category experiences a rapid surge in consumer demand and media coverage.REVIEWED

Why fake reviews carry extra weight in health-related purchases

Consumers researching a weight-loss program often rely heavily on other users' reported experiences and outcomes, since a prospective buyer generally cannot verify a medication's effectiveness for themselves before committing to a membership or a prescription. That reliance makes fabricated testimonials especially consequential in this category compared to lower-stakes consumer products, since a fake review claiming dramatic weight-loss results can directly shape a health-related purchasing decision that carries real financial and physical stakes.REVIEWED

For consumers evaluating any telehealth weight-loss program, the NextMed case underscores the value of requesting complete, itemized pricing — including membership fees, medication costs, and any recurring charges — in writing before enrolling, rather than relying on a marketing page's summary price that may not reflect the program's actual total cost.REVIEWED

The $150,000 settlement figure, modest compared to some other health-marketing cases, reflects the company's more limited scale rather than a lesser degree of alleged deception — a reminder that regulators pursue cases based on the underlying conduct at issue, not solely on the dollar volume a company generates, since a smaller telehealth operator's deceptive claims can still cause real harm to the individual consumers who relied on them.REVIEWED As the GLP-1 telehealth market continues to grow, the case is likely to serve as an early marker for how regulators expect pricing and testimonial claims in this specific category to be handled going forward, including how membership terms must be disclosed and how testimonials must be substantiated before they can appear in marketing materials. Other telehealth operators marketing similar programs may find themselves measured against the same specific standard this settlement establishes, particularly as the number of companies entering this space continues to expand alongside consumer demand for GLP-1 access. Consumers researching any weight-loss telehealth provider can look specifically for independently verifiable outcome data rather than relying on testimonials featured on the company's own marketing pages, and can check whether pricing quoted upfront matches what actually appears on their first bill. A company unwilling to put its full membership terms in writing before a consumer signs up is itself a signal worth taking seriously, regardless of how compelling the rest of its marketing pitch may sound.REVIEWED

Have documents relevant to this story? Reach us through our tips channel.